Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 18%
Buy 53%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. has demonstrated a notable increase in spending, with a reported 56% increase in 3Q25, which is anticipated to continue into 4Q25 and throughout 2026, promoting awareness and procedure volumes. The company has reiterated its revenue guidance for 2025 and has raised its full-year GAAP EPS estimate by $0.50 per share following a strong earnings beat in 3Q. Despite a year-to-date decline of 26% in stock price, shares have surged approximately 86% since the Q3 earnings report release, largely driven by favorable updates and improved reimbursement outlooks that are expected to elevate average selling prices (ASPs).

Bears say

Inspire Medical Systems faces a negative outlook primarily due to a slowdown in advertising spending, with projections indicating a 5% year-over-year decrease in 2024 and a further 6% decline in the first half of 2025. The launch of the Inspire 5 product has encountered more challenges than expected, leading management to revise revenue and earnings-per-share forecasts downward, which impacts stock valuation. Additionally, operational expenditures have decreased, reflecting cuts to research and development and selling, general, and administrative costs, indicating potential challenges in sustaining growth and innovation in a competitive market.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 53% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $138.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $138.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.